Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
Manraj N. KaurDonald M. ArnoldNancy M. HeddleRichard J. CookCyrus C. HsiaMark BlosteinErin JamulaMichelle SholzbergYulia LinJeannine KassisLoree LarrattAlan TinmouthJulie CarruthersNa LiYang LiuFeng Xie
10
Citation
30
Reference
10
Related Paper
Citation Trend
Abstract:
Eltrombopag has been shown to be noninferior to intravenous immunoglobulin (IVIG) for improving perioperative platelet counts in patients with immune thrombocytopenia (ITP) in a randomized trial; thus, cost is an important factor for treatment and policy decisions. We used patient-level data from the trial to conduct a cost-effectiveness analysis comparing perioperative eltrombopag 50 mg daily starting dose, with IVIG 1 or 2 g/kg (according to local practice) from a Canadian public health care payer's perspective over the observation period, from preoperative day 21 to postoperative day 28. Resource utilization data were obtained from the trial data (eltrombopag, n = 38; IVIG, n = 36), and unit costs were collected from the Ontario Schedule of Benefits, Ontario Drug Formulary, and secondary sources. All costs were adjusted to 2020 Canadian dollars. We calculated the incremental cost per patient for all patients randomized. Uncertainty was addressed using nonparametric bootstrapping. The use of perioperative eltrombopag for patients with ITP resulted in a cost-saving of $413 Canadian per patient. Compared with IVIG, the probability of eltrombopag being cost effective was 70% even with no willingness to pay. In a sensitivity analysis based on IVIG dose, we found that with the higher dose of IVIG (2 g/kg), eltrombopag saved $2,714 per patient, whereas with the lower dose of IVIG (1 g/kg), eltrombopag had a higher mean cost of $562 per patient. In summary, based on data from the randomized trial that demonstrated noninferiority, the use of eltrombopag for the management of ITP in the perioperative setting was less costly than IVIG.Keywords:
Eltrombopag
Eltrombopag
Romiplostim
Cite
Citations (0)
Eltrombopag
Romiplostim
Hematology
Cite
Citations (3)
Eltrombopag
Primary (astronomy)
Cite
Citations (0)
Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis and colleagues, and how to move forward with these patients. Commentary on: Moulis et al. Difficult-to-treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN-France Registry. Br J Haematol 2024;204:1476-1482.
Romiplostim
Eltrombopag
Refractory (planetary science)
Thrombopoietin receptor
Cite
Citations (1)
Introduction: Pediatric immune thrombocytopenia (ITP) may be associated with significant burden on children and their parents/caregivers. Thrombopoietin (TPO) receptor agonists (RAs) have been used to treat adult patients with chronic ITP (cITP) for nearly a decade and following pediatric studies Eltrombopag has been recently approved for pediatric cITP in the United States and Europe. TPO-RA s may help reduce the risk of bleeding and the need for conventional ITP therapies.Review: In this review, the clinical data demonstrating the efficacy and safety of TPO-RAs in pediatric ITP are evaluated, key recommendations regarding safe administration of eltrombopag are provided, and potential future directions in management of pediatric ITP are discussed.
Eltrombopag
Romiplostim
Thrombopoietin receptor
Cite
Citations (14)
Key Clinical Message Children with immune thrombocytopenia ( ITP ) are often managed using a watch‐and‐wait approach to avoid conventional treatment that may be poorly tolerated. However, in some patients, this approach may lead to lifestyle restrictions due to risk of injury‐related bleeding. Eltrombopag is a well‐tolerated new option that may help these children.
Eltrombopag
Major bleeding
Cite
Citations (3)
Eltrombopag
Cite
Citations (0)
Summary The PETIT (Eltrombopag in Pe diatric Patients with T hrombocytopenia from Chronic IT P) trial showed that in children aged 1–17 years with chronic or persistent immune thrombocytopenia (ITP), eltrombopag improved platelet counts, decreased clinically significant bleeding and reduced rescue medication need. We report the health‐related quality of life (HRQoL) results from the PETIT study using the Kids’ ITP Tools (KIT). A limitation was that PETIT was not powered for the HRQoL analysis. Eltrombopag did not impact children's HRQoL assessed by the KIT. Although median KIT scores in children treated with eltrombopag with platelet responses were numerically higher compared with non‐responders in some age groups, the interquartile ranges overlapped.
Eltrombopag
Interquartile range
Cite
Citations (15)
Eltrombopag
Refractory (planetary science)
Romiplostim
Cite
Citations (1)